Zepbound and Reproductive Health: What to Know About Pregnancy, Breastfeeding, and Birth Control 

Tirzepatide, sold under the brand name Zepbound, is a weight-loss drug that works on two gut hormones at once (GIP and GLP-1). More and more people of childbearing age are starting this medication, which means doctors are fielding a lot of questions about pregnancy planning, breastfeeding, and how the drug might affect birth control. Here’s a plain-language look at what’s known so far.

How Zepbound Works, and Why It Matters for Reproductive Health

Zepbound is approved for long-term weight loss in adults who are overweight or obese and have at least one weight-related health issue. It’s also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

The drug curbs appetite and slows down how fast food leaves your stomach. That slower digestion is exactly what makes this relevant to reproductive health  because it can also slow down how quickly your body absorbs other pills you’re taking, including birth control pills. That’s a big reason doctors bring this topic up early with patients.

Pregnancy: Current Guidance

Zepbound isn’t recommended during pregnancy. Losing weight while pregnant doesn’t help the mother and could potentially harm the baby, based on animal studies and what limited human data exist so far.

If you become pregnant while taking Zepbound, stop the medication right away and call your doctor. They’ll help you switch to a safer approach for managing your weight and get you set up with proper prenatal care.

Because there isn’t much human safety data yet, the drugmaker runs a pregnancy registry, basically a way to track outcomes for people who were exposed to the drug during pregnancy, so researchers can learn more over time. Anyone who becomes pregnant on Zepbound can enroll through the registry’s website or hotline.

For people who aren’t breastfeeding, restarting weight-loss treatment after giving birth may be an option once the body has recovered. That timing should be worked out with a doctor, since it depends on things like how the delivery went and overall recovery.

Breastfeeding

For nursing parents, the main question is whether the drug shows up in breast milk. In a small study of healthy breastfeeding women, tirzepatide wasn’t detectable in breast milk at all. That’s reassuring, but it’s not the whole picture. Nobody has yet studied whether the drug affects milk supply or the baby’s growth over time.

Because of that gap, the decision to use Zepbound while breastfeeding should be a conversation with your doctor, weighing the well-known benefits of breastfeeding against your need for weight management treatment.

Birth Control: The Important Interaction

Anyone who can get pregnant and is sexually active should talk about birth control before starting Zepbound and keep that conversation going throughout treatment, not just at the start.

Here’s the key issue: because Zepbound slows down digestion, it can also reduce how well your body absorbs birth control pills. That means the pill could be less effective at certain points during treatment, raising the risk of an unplanned pregnancy.

To get around this, doctors usually suggest switching to a birth control method that doesn’t rely on the stomach to work like a patch or a vaginal ring or adding a backup method like condoms. The official prescribing label calls for extra precautions for the first four weeks after starting the drug, and again for four weeks after every dose increase, since that’s when the slowdown in digestion tends to be strongest.

What This Means for Doctors and Patients

Given all this, it makes sense for doctors to ask about pregnancy status, plans for pregnancy, breastfeeding, and current birth control at every visit not just once. Writing this down in the chart helps, especially if a patient sees more than one provider. Clear, simple handouts about the birth-control-pill interaction can also go a long way toward keeping patients protected. Because the breastfeeding data is still thin, doctors are better off making these calls case by case rather than following a one-size-fits-all rule.

What We Still Don’t Know

Right now, most of what’s known about Zepbound and pregnancy comes from animal studies and a small amount of human data, backed up by an understanding of how the drug works in the body. The pregnancy registry should add more real-world evidence as more people enroll. Dedicated studies on breastfeeding looking at milk supply and how babies actually grow would help close a real gap in the research.

Until then, caution during pregnancy and case-by-case decisions during breastfeeding remain the sensible approach. Patients who do become pregnant while on the drug are encouraged to join the registry so future guidance can be more precise.

Conclusion

Zepbound raises a few reproductive health questions worth planning for ahead of time: it’s not advised during pregnancy, the breastfeeding data is reassuring but incomplete, and it can weaken birth control pills at certain points in treatment. The pill interaction is manageable non-oral birth control or a backup method during the risk windows does the trick. As more registry data comes in and more research gets done on breastfeeding, doctors should be able to offer clearer, more personalized guidance over time.

References

Eli Lilly and Company. (2026). Zepbound (tirzepatide) injection, for subcutaneous use: Prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf

Eli Lilly and Company. (2026). Zepbound pregnancy registry. https://pregnancyregistry.lilly.com/zepbound

U.S. Food and Drug Administration. (2023). FDA approves new medication for chronic weight management. https://www.fda.gov/drugs/news-events-human-drugs